Abstract
The identification and management of individuals with a genetic risk for breast cancer have changed dramatically over the past few years. Mutations in genes besides BRCA1 and BRCA2 have been associated with hereditary breast cancer risk. Genetic testing technology has improved allowing for the testing of numerous genes at once. As our understanding of the cancer risks conferred by different mutations has deepened, cancer screening and risk reduction recommendations for affected individuals have changed. Many families with a history of breast cancer have no identifiable causative genetic mutation, however, they are still at increased risk due to a combination of unknown genetic factors, as well as environmental and lifestyle effects. Current methods for risk assessment, genetic counseling and testing, and management of individuals at hereditary risk for breast cancer will be covered, as well as resources for including these activities into clinical practice.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet. 1986;22(4):369–71.
Jain R, et al. The relevance of hereditary cancer risks to precision oncology: what should providers consider when conducting tumor genomic profiling? J Natl Compr Canc Netw. 2016;14(6):795–806.
Easton DF, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243–57.
Mavaddat N et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107(5).
Evans DG, et al. Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prevent Res. 2012;5(7):943–51.
Ford D, et al. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet. 1994;343(8899):692–5.
Frank TS, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16(7):2417–25.
Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57(6):1457–62.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V.1.2017. 2016.
Metcalfe KA, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28(3):387–91.
Petrij-Bosch A, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997;17(3):341–5.
Johannesdottir G, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996;56(16):3663–5.
Mavaddat N. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. 2013;105(11):812–22.
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.
Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22(4):735–42.
Schneider BP, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.
Lakhani SR, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.
Bane AL, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007;31(1):121–8.
Lu KH, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18(14):2728–32.
Sherman ME, et al. Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int J Gynecol Pathol. 1999;18(2):151–7.
Levine DA, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21(22):4222–7.
Harmsen MG, et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomized multicentre study. BMC Cancer. 2015;15:593.
Anon (1999) Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst. 1999;91(15):1310–6.
Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene. 2006;25(43):5825–31.
Agalliu I, et al. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res. 2009;15(3):1112–20.
Narod SA, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008;99(2):371–4.
Castro E, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748–57.
Howlett NG, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297(5581):606–9.
Schreibman IR, et al. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol. 2005;100(2):476–90.
Pilarski R, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105(21):1607–16.
Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7.
Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumor syndrome. J Med Genet. 2004;41(5):323–6.
Olivier M, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643–50.
Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21(3):313–20.
Lustbader ED, et al. Segregation analysis of cancer in families of childhood soft tissue sarcoma patients. Am J Hum Genet. 1992;51(2):344–56.
Birch JM, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20(34):4621–8.
Hisada M, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90(8):606–11.
Villani A, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12(6):559–67.
Giardiello FM, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987;316(24):1511–4.
Hearle N, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.
Mehenni H, et al. Cancer risks in LKB1 germline mutation carriers. Gut. 2006;55(7):984–90.
Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol. 2006;4(4):408–15.
Hansford S et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.
van der Post RS, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–74.
Petridis C, et al. Germline CDH1 mutations in lobular carcinoma in situ. Br J Cancer. 2014;110(4):1053–7.
Xia B, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22(6):719–29.
Antoniou AC, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506.
Schneider R, et al. German national case collection for familial pancreatic cancer (FaPaCa): 10 years experience. Fam Cancer. 2011;10(2):323–30.
Tischkowitz M, et al. PALB2/FANCN: recombining cancer and Fanconi Anemia. Cancer Res. 2010;70(19):7353–9.
Geoffroy-Perez B, et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer. 2001;93(2):288–93.
Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol. 2016;40(5):425–31.
Tavtigian S, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009;85(4):427–46.
Roberts NJ, et al. ATM mutations in hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–6.
Schmidt MK et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC Carriers. J Clin Oncol. 2016; Epub ahead of print: June 6, 2016.
Weischer M, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analysis of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26(4):542–8.
Cybulski C, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2008;75(6):1131–5.
Damiola F, et al. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibilty: results from a breast cancer family registry case-control mutation screening study. Breast Cancer Res. 2014;16(3):R58.
Ito A, et al. Expression of full-length NBS1 protein restores normal radiation responses in cells from Nijmegen breakage syndrome patients. Biochem Biophys Res Commun. 1999;265(3):716–21.
Bennett IC, Gattas M, Teh BT. The management of familial breast cancer. Breast. 2000;9(5):247–63.
Hoskins KF, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995;273(7):577–85.
Bennett RL, et al. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns. 2008;17(5):424–33.
Schneider KA, et al. Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test. 2004;8(3):222–8.
Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a casecontrol study. Am J Epidemiol. 1997;146(3):244–8.
Ziogas A, Anton-Culver H. Validation of family history data in cancer family registries. Am J Prev Med. 2003;24(2):190–8.
Acheson LS, et al. Family history-taking in community family practice: implications for genetic screening. Genet Med. 2000;2(3):180–5.
Weitzel JN, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297(23):2587–95.
Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.
Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7(2):149–56.
Boffetta P, et al. The burden of cancer attributable to alcohol drinking. Int J Cancer. 2006;119(4):884–7.
Boyd NF, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227–36.
Zheng T, et al. Radiation exposure from diagnostic and therapeutic treatments and risk of breast cancer. Eur J Cancer Prev. 2002;11(3):229–35.
El-Gamal H, Bennett RG. Increased breast cancer risk after radiotherapy for acne among women with skin cancer. J Am Acad Dermatol. 2006;55(6):981–9.
Hopwood P, et al. Do women understand the odds? Risk perceptions and recall of risk information in women with a family history of breast cancer. Community Genet. 2003;6(4):214–23.
Woloshin S, Schwartz LM, Welch HG. Risk charts: putting cancer in context. J Natl Cancer Inst. 2002;94(11):799–804.
Prasad K, et al. Tips for teachers of evidence-based medicine: understanding odds ratios and their relationship to risk ratios. J Gen Intern Med. 2008;23(5):635–40.
Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk; the Utah Population Database. JAMA. 1993;270:1563.
Gail MH, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst. 1994;86(8):573–5.
Rockhill B, et al. Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66.
Claus EB, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77(11):2318–24.
Berry DA, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701–12.
Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet. 2000;58(4):299–308.
Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62(1):145–58.
Antoniou AC, et al. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res. 2006;8(1):R3.
Lee AJ et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet in Med. 2016; Epub April 14, 2016.
Trepanier A, et al. Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2004;13(2):83–114.
Kinney AY. Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial. J Natl Cancer Inst. 2014;106(12).
Gabai-Kapara E. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA. 2014;111(39):14205–10.
Claes E, et al. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A. 2003;116(1):11–9.
Press N, et al. Women’s interest in genetic testing for breast cancer susceptibility may be based on unreasonable expectations. Am J Med Genet. 2001;99:99–110.
Hudson KL, et al. Genetic discrimination and health insurance: an urgent need for reform. Science. 1995;270(5235):391–3.
Hudson KL, Holohan MK, Collins FS. Keeping pace with the times–the genetic information nondiscrimination act of 2008. N Engl J Med. 2008;358(25):2661–3.
Bradbury AR, et al. How often do BRCA mutation carriers tell their young children of the family’s risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007;25(24):3705–11.
Bradbury AR, et al. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008;148C(1):70–7.
Bradbury AR et al. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. 2012;118(13):3417–25.
den Dunnen JT, et al. HGVS recommendations for description of sequence variants: 2016 Update. Hum Mutat. 2016;37(6):564–9.
Plon S, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282–91.
Warner E, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25.
Plevritis SK, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295(20):2374–84.
Gail MH, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829–46.
Hendrick RE, et al. Benefit of screening mammography in women aged 40–49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr. 1997;22:87–92.
Moss SM, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomized controlled trial. Lancet. 2006;368(9552):2053–60.
Passaperuma K, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107:24–30.
Pijpe A, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660.
Lowry KP, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer. 2012;118:2021–30.
Baxter N. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? CMAJ. 2001;164(13):1837–46.
Saslow D, et al. Clinical Breast Examination: Practical Recommendations for Optimizing Performance and Reporting. CA Cancer J Clin. 2004;54:327–44.
Gaskie S, Nashelsky J. Clinical inquires. Are breast self-exams or clinical exams effective for screening breast cancer. J Fam Pract. 2005;54(9):803–4.
Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.
Gronwald J, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281–4.
King MC, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA. 2001;286:2251–6.
Vogel VG, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.
Cuzick J, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041–8.
Goss PE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.
Kauff ND, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–7.
Greene MH et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design Prev. 2008;17(3):594–604.
Rebbeck TR, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2005;23(31):7804–10.
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.
Gabriel CA, et al. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer. 2009;8(1):23–8.
Rebbeck TR, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2005;23(31):7804–10.
Hartmann LC, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84.
Hartmann LC, Degnim A, Schaid DJ. Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol. 2004;22(6):981–3.
Rebbeck TR, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22(6):1055–62.
Clarke M. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.
Valsecchi ME, et al. Role of carboplatin in the treatment of triple negative early-stage breast cancer. Rev Recent Clin Trials. 2015;10(2):101–10.
Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.
Patenaude AF, et al. Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol. 2006;24(4):700–6.
MacDonald DJ, et al. Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med. 2007;9(5):275–82.
McGivern B, et al. Family communication about positive BRCA1 and BRCA2 genetic test results. Genet Med. 2004;6(6):503–9.
Forrest LE, et al. Increased genetic counseling support improves communication of genetic information in families. Genet Med. 2008;10(3):167–72.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Colonna, S., Gammon, A. (2016). Management of the Patient with a Genetic Predisposition for Breast Cancer. In: Jatoi, I., Rody, A. (eds) Management of Breast Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-46356-8_31
Download citation
DOI: https://doi.org/10.1007/978-3-319-46356-8_31
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46354-4
Online ISBN: 978-3-319-46356-8
eBook Packages: MedicineMedicine (R0)